keyboard_arrow_up

Obama’s Healthcare Reform Bill and its impact on the U.S. healthcare market (Pharmaceuticals, Medical devices and health insurance)

This report forecasts the future impacts of the Health Reform bill enacted by President Obama in March 2010. The report focuses on the U.S. healthcare system and its major stakeholders such as pharmaceutical manufacturers, medical devices manufacturers, and health insurance industry.

Browse in-depth TOC on Obama’s Healthcare Reform Bill and its impact on the U.S. Healthcare Market. Early buyers will receive 10% customization of reports
http://www.marketsandmarkets.com/Market-Reports/Impact-Obama-Health-US-240.html

The health reform bill set forth several provisions to improve the quality and efficiency of healthcare, address the inefficiencies of the existing healthcare structure, and to decrease the number of uninsured people in the U.S. In order to implement a self-funded reform, the Obama Administration set forward provisions for cost containment and assessment of annual fees (in the form of excise tax) on drug manufacturers, medical device companies, and the private insurance industry over a period of 2010 to 2019. Successful implementation of the health reforms by 2019 would reduce federal budgetary deficit by $143 billion from about $1.4 trillion in 2009.

Buy Now @ http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=240

The industry-specific provisions of the health reforms are expected to have a mixed impact on drug manufacturers and medical device industry. Evaluating the health reforms from the perspective of changing equation among industry stakeholders, empowerment of consumers in the long run is likely to create a win-win situation for all stakeholders.

SCOPE AND FORMAT 
The report forecasts and analyzes the future impact of the health reforms on the U.S. healthcare industry. This covers direct as well as indirect impacts of the provisions on pharmaceutical, medical devices, and health insurance industries. Indirect impact refers to provisions that do not specifically apply to these industries. Each section offers a strategic analysis of the impact of Obama’s health reforms on the U.S. healthcare structure.

About MarketsandMarkets

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan

North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252 
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com